Transformative immunomodulating medicines for patients May 2025 1 Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may", "will", "believe", "expect", "plan", "anticipate", "estimate" and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. All statements ...

Immunocore Holdings (IMCR) 2025 Conference June 05, 2025 11:05 AM ET Speaker0 Welcome everyone to the next session. I'm Michael Yee, Senior Biotechnology Analyst at Jefferies and I'm Speaker1 very pleased to have members of the Immunocor team up here with us. David Berman, Chief Scientific Officer and Ralph Torbay, the Chief Commercial Officer. Fantastic duo bunch because we're going to talk about revenues and sales and an approved drug in the commercial side. And, we're also going to Speaker0 talk with Dav ...

Shares of Immunocore Holdings PLC Sponsored ADR (IMCR) have gained 20.2% over the past four weeks to close the last trading session at $36.60, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $60.47 indicates a potential upside of 65.2%.The average comprises 15 short-term price targets ranging from a low of $24 to a high of $100, with a standard deviation of $21.18. While the low ...

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, June 2, 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in the 2025 Jefferies Global Healthcare Conference. 2024 Jefferies Global Healthcare ConferenceFir ...

Immunocore (IMCR) is witnessing a strong sales uptake for its sole marketed drug, Kimmtrak (tebentafusp-tebn), which is approved for treating patients with unresectable or metastatic uveal melanoma (mUM).Kimmtrak is approved in 39 countries, including the United States, the European Union, Canada, and others. The product has been launched in 26 countries worldwide and continues to be the standard of care for mUM in most markets where it has been launched.Kimmtrak generated sales worth $310 million in 2024, ...

Group 1 - Immunocore Holdings PLC (IMCR) closed at $29.06, with a 2.3% gain over the past four weeks, and has a mean price target of $62.29, indicating an upside potential of 114.4% [1] - The average of 14 short-term price targets ranges from a low of $24 to a high of $100, with a standard deviation of $23.44, suggesting variability in analyst estimates [2] - Analysts show strong agreement on the company's ability to report better earnings than previously predicted, which supports the view of potential upside [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 42.9% over the last 30 days, with seven estimates moving higher and no negative revisions [12] - IMCR holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting the extent of gains, they can indicate the direction of price movement [13]

For the quarter ended March 2025, Immunocore Holdings PLC Sponsored ADR (IMCR) reported revenue of $93.88 million, up 33.2% over the same period last year. EPS came in at $0.10, compared to -$0.49 in the year-ago quarter.The reported revenue represents a surprise of +7.84% over the Zacks Consensus Estimate of $87.06 million. With the consensus EPS estimate being -$0.35, the EPS surprise was +128.57%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how t ...

"We are thrilled to have achieved strong revenue performance in Q1, marked by year-over-year growth of 33%. This reflects our unwavering dedication to making KIMMTRAK accessible to patients who need it," said Bahija Jallal, Chief Executive Officer of Immunocore. "In R&D, we continue to be laser-focused on execution in our oncology franchise with three ongoing Phase 3 trials and a promising early pipeline. We are also excited to have presented the initial MAD data at CROI from our ongoing HIV trial, which, t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-39992 Immunocore Holdings plc (Exact name of registrant as specified in its charter) | England and Wales | Not A ...

Immunocore reports first quarter financial results and provides a business update KIMMTRAK (tebentafusp-tebn) net revenues of $93.9 million in Q1 2025, growing by 33% year-over-year On track for Phase 3 TEBE-AM trial to complete enrollment in 1H 2026 On track for dose selection in Phase 3 PRISM-MEL-301 trial in 2H 2025 Initial multiple ascending dose data for HIV functional cure candidate presented during oral session at CROI 2025; dose escalation ongoing Cash, cash equivalents and marketable securities of ...